The supply agreement supports the evaluation of Immuneerings' lead product candidate, IMM-1-104, in combination with Regeneron's immunotherapy drug Libtayo in patients with advanced non-small cell ...
The supply agreement supports the evaluation of Immuneering’s lead product candidate, IMM-1-104, in combination with Libtayo in patients with unresectable or metastatic RAS-mutant non-small cell ...
Regeneron stock rose early Tuesday on a strong fourth-quarter report that included in-line sales of eye drug Eylea.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback